N/A
Manufactured by Encube Ethicals, Inc.
17,987 FDA adverse event reports analyzed
Last updated: 2026-04-14
DAPSONE GEL, 5% is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Encube Ethicals, Inc.. The most commonly reported adverse reactions for DAPSONE GEL, 5% include OFF LABEL USE, DRUG INEFFECTIVE, PYREXIA, NAUSEA, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DAPSONE GEL, 5%.
Out of 9,248 classified reports for DAPSONE GEL, 5%:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 17,987 FDA FAERS reports that mention DAPSONE GEL, 5%. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, DRUG INEFFECTIVE, PYREXIA, NAUSEA, FATIGUE, METHAEMOGLOBINAEMIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Encube Ethicals, Inc. in connection with DAPSONE GEL, 5%. Always verify the specific product and NDC with your pharmacist.